On 3 June 2008, orphan designation (EU/3/08/549) was granted by the European Commission to MolMed S.p.A, Italy, for NGR-human Tumour Necrosis Factor for the treatment of malignant mesothelioma.
NGR-human tumour necrosis factor
|Disease / condition||
Treatment of malignant mesothelioma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: